348 results
SC TO-T/A
EX-99
Swedish Orphpan Biovitrum AB
26 Jun 23
Third party tender offer statement (amended)
9:20am
a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product, VONJO® (pacritinib), a JAK2, ACVR1, and IRAK1 inhibitor
SC TO-T/A
EX-99
Swedish Orphpan Biovitrum AB
26 Jun 23
Third party tender offer statement (amended)
9:20am
on the development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare
DEFA14A
CTIC
CTI BioPharma Corp
30 May 23
Additional proxy soliciting materials
5:21pm
and their healthcare providers. CTI has one FDA-approved product, VONJO® (pacritinib), a JAK2, ACVR1, and IRAK1 inhibitor, that spares JAK1. VONJO
8-K
EX-99.1
CTIC
CTI BioPharma Corp
30 May 23
CTI BioPharma Announces Cancellation of its 2023 Annual Meeting of Stockholders
5:20pm
targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product
SC 14D9
CTIC
CTI BioPharma Corp
25 May 23
Tender offer solicitation
7:00am
a healthcare conference. The Chief Executive Officer of Company A reiterated Company A’s interest in a strategic transaction involving CTI.
On December 21
SC TO-T
EX-99
ygtaexcj4zx wbrt0
25 May 23
Third party tender offer statement
6:46am
SC TO-T
EX-99
5ncot13ichvkl7nbwulm
25 May 23
Third party tender offer statement
6:46am
SC TO-C
EX-99.2
2yzlnupr bztf7qv6
10 May 23
Information about tender offer
5:01pm
SC TO-C
EX-99.1
i5lgyxi
10 May 23
Information about tender offer
5:01pm
SC14D9C
EX-99.3
8edz45lr7d7pucp462
10 May 23
Written communication relating to third party tender offer
2:02pm
SC14D9C
EX-99.1
ojyf4r54z r1o0g4h
10 May 23
Written communication relating to third party tender offer
2:02pm
SC14D9C
EX-99.4
bsqjnj 6gst8ce
10 May 23
Written communication relating to third party tender offer
2:02pm
SC14D9C
EX-2.1
76xe1jvr6iaf961ody
10 May 23
Written communication relating to third party tender offer
1:30pm
SC14D9C
EX-99.2
6ejl21
10 May 23
Written communication relating to third party tender offer
1:30pm
8-K
EX-99.2
nen20 f5w1yn
10 May 23
Tender and Support Agreement
8:05am
8-K
EX-2.1
4rg6wau8h nr7ske7g
10 May 23
Tender and Support Agreement
8:05am
8-K
EX-99.1
mxacr4jovyy1
7 Nov 22
CTI BioPharma Reports Third Quarter 2022 Financial Results
4:07pm